Search research articles
Contact Us
Filters
Showing results (181-190 of 288) with videos related to
Page
of 29
Sort By:
HIV Clinical Trials
|
March 18, 2017
Efficacy and safety of emtricitabine/tenofovir alafenamide (FTC/TAF) vs. emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) as a backbone for treatment of HIV-1 infection in virologically suppressed adults: subgroup analysis by third agent of a randomized, double-blind, active-controlled phase 3 trial<sup/>
Frank A Post, Yazdan Yazdanpanah, Gabriel Schembri, et al.
Lancet (London, England)
|
July 19, 2011
Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial
Jean-Michel Molina, Pedro Cahn, Beatriz Grinsztejn, et al.
Lancet (London, England)
|
August 8, 2006
Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials
Charles B Hicks, Pedro Cahn, David A Cooper, et al.
International Journal of Cancer
|
July 29, 2011
Ten-year survival among HIV-1-infected subjects with AIDS or non-AIDS-defining malignancies
Vincenzo Spagnuolo, Laura Galli, Stefania Salpietro, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
February 17, 2005
Prognostic significance of JC virus DNA levels in cerebrospinal fluid of patients with HIV-associated progressive multifocal leukoencephalopathy
Simona Bossolasco, Giliola Calori, Francesca Moretti, et al.
The New Microbiologica
|
August 24, 2016
Monotherapy with darunavir/ritonavir or lopinavir/ritonavir versus standard antiretroviral therapy: a randomized clinical trial (2pm Study)
Nicola Gianotti, Laura Galli, Renato Maserati, et al.
Antiviral Therapy
|
November 3, 2010
Unboosted atazanavir-based therapy maintains control of HIV type-1 replication as effectively as a ritonavir-boosted regimen
Jade Ghosn, Giampiero Carosi, Santiago Moreno, et al.
The Journal of Antimicrobial Chemotherapy
|
May 20, 2008
Pharmacokinetic and pharmacodynamic determinants of early virological response to enfuvirtide-based regimens in HIV-positive patients
Daniel Gonzalez de Requena, Stefano Bonora, Antonella Castagna, et al.
The New Microbiologica
|
October 6, 2016
48 week outcomes of maraviroc-containing regimens following the genotypic or Trofile assay in HIV-1 failing subjects: the OSCAR Study
Silvia Nozza, Angela Rosa Pignataro, Laura Galli, et al.
AIDS (London, England)
|
July 25, 2014
Simplification to atazanavir/ritonavir monotherapy for HIV-1 treated individuals on virological suppression: 48-week efficacy and safety results
Antonella Castagna, Vincenzo Spagnuolo, Laura Galli, et al.
Page
of 29
Search research articles
Search
Showing results (181-190 of 288) with videos related to
Sort By:
Page
of 29
HIV Clinical Trials
|
March 18, 2017
Efficacy and safety of emtricitabine/tenofovir alafenamide (FTC/TAF) vs. emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) as a backbone for treatment of HIV-1 infection in virologically suppressed adults: subgroup analysis by third agent of a randomized, double-blind, active-controlled phase 3 trial<sup/>
Frank A Post, Yazdan Yazdanpanah, Gabriel Schembri, et al.
Lancet (London, England)
|
July 19, 2011
Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial
Jean-Michel Molina, Pedro Cahn, Beatriz Grinsztejn, et al.
Lancet (London, England)
|
August 8, 2006
Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials
Charles B Hicks, Pedro Cahn, David A Cooper, et al.
International Journal of Cancer
|
July 29, 2011
Ten-year survival among HIV-1-infected subjects with AIDS or non-AIDS-defining malignancies
Vincenzo Spagnuolo, Laura Galli, Stefania Salpietro, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
February 17, 2005
Prognostic significance of JC virus DNA levels in cerebrospinal fluid of patients with HIV-associated progressive multifocal leukoencephalopathy
Simona Bossolasco, Giliola Calori, Francesca Moretti, et al.
The New Microbiologica
|
August 24, 2016
Monotherapy with darunavir/ritonavir or lopinavir/ritonavir versus standard antiretroviral therapy: a randomized clinical trial (2pm Study)
Nicola Gianotti, Laura Galli, Renato Maserati, et al.
Antiviral Therapy
|
November 3, 2010
Unboosted atazanavir-based therapy maintains control of HIV type-1 replication as effectively as a ritonavir-boosted regimen
Jade Ghosn, Giampiero Carosi, Santiago Moreno, et al.
The Journal of Antimicrobial Chemotherapy
|
May 20, 2008
Pharmacokinetic and pharmacodynamic determinants of early virological response to enfuvirtide-based regimens in HIV-positive patients
Daniel Gonzalez de Requena, Stefano Bonora, Antonella Castagna, et al.
The New Microbiologica
|
October 6, 2016
48 week outcomes of maraviroc-containing regimens following the genotypic or Trofile assay in HIV-1 failing subjects: the OSCAR Study
Silvia Nozza, Angela Rosa Pignataro, Laura Galli, et al.
AIDS (London, England)
|
July 25, 2014
Simplification to atazanavir/ritonavir monotherapy for HIV-1 treated individuals on virological suppression: 48-week efficacy and safety results
Antonella Castagna, Vincenzo Spagnuolo, Laura Galli, et al.
Page
of 29